Press-release for stocks related to phase 2 listed in the nasdaq exchange

Prices are updated after-hours

tags : Phase 2 exchanges : Nasdaq

save search

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Published: 2023-12-05 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K

| 7.38% | O: -30.2% H: 20.19% C: 8.65%
als trial phase 2

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Published: 2023-12-05 (Crawled : 12:30) - globenewswire.com
ALLR | $1.53 2.0% 1.96% 760K

n/a

| 153.38% | O: 66.69% H: 11.0% C: -42.04%
drp diagnostic cancer women companion advanced phase 2

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K

Health Technology

| -76.51% | O: 6.63% H: 12.99% C: 6.78%
rhb-107 covid-19 funding study phase 2

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
APLM | $0.51 -3.77% -3.92% 100K

n/a

| -42.69% | O: 2.53% H: 0.22% C: -17.21%
ongoing trials phase 2

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
ALT | $6.9 -1.99% -2.03% 3.2M

Commercial Services

| 140.26% | O: 1.28% H: 5.68% C: -0.32%
obesity momentum positive topline trial results phase 2

Telesat Government Solutions Awarded DARPA Space-BACN Phase 2 Contract
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
TSAT | $7.97 0.63% 0.63% 27K

| -27.89% | O: 0.28% H: 5.81% C: 3.46%
contract solutions phase 2

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
SKYE | $16.865 -2.85% -2.94% 70K

Transportation and Warehousing

| 1020.0% | O: 3.23% H: 6.25% C: -3.13%
sbi-100 glaucoma bioscience study phase 2

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
ACAD | $17.08 -0.64% -0.64% 990K

Health Technology

| -22.79% | O: -0.45% H: 0.41% C: -0.32%
acp-204 disease alzheimer’s treatment pharmaceuticals trial phase 2

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ROIV | $10.37 -0.67% -0.68% 3.4M

Manufacturing

| 14.35% | O: -3.29% H: 3.34% C: 3.06%
lupus results study phase 2

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Published: 2023-11-22 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -0.36% | O: -0.74% H: 0.71% C: 0.71%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 25.54% | O: -0.44% H: 0.63% C: -0.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -1.03% | O: -0.34% H: 0.0% C: 0.0%
ibi362 publication care chinese diabetes results phase 2

Rigetti Computing Awarded Phase 2 of DARPA Benchmarking Program
Published: 2023-11-21 (Crawled : 13:30) - globenewswire.com
RGTI | $1.175 -0.42% -0.43% 2.6M

| 12.38% | O: 0.0% H: 0.0% C: -2.86%
program phase 2

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
Published: 2023-11-20 (Crawled : 13:30) - globenewswire.com
ATOS | $1.41 4.44% 4.26% 2.3M

Health Technology

| 126.47% | O: -0.34% H: 9.19% C: 9.19%
trial therapeutics phase 2

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
Published: 2023-11-16 (Crawled : 00:00) - biospace.com/
ASND | $140.98 -0.84% -0.84% 220K

Health Technology

| 52.2% | O: 0.39% H: 0.71% C: 0.18%
trial china phase 2

Akoustis Awarded Phase 2 For DARPA COFFEE Program
Published: 2023-11-16 (Crawled : 12:00) - globenewswire.com
AKTS | $0.5296 4.91% 4.68% 340K

Electronic Technology

| -33.18% | O: 9.51% H: 0.27% C: -16.89%
program phase 2

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
IGXT | $0.16 -19.77% 47K

Manufacturing

| 27.69% | O: 7.74% H: 1.85% C: -0.96%
versafilm disease parkinson's approval montelukast trial phase 2

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Published: 2023-11-14 (Crawled : 06:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology